Rating Card

premiumPremium content

Unlock Expert's Rating and Top Picks Portfolio

Curated by Michael O'Reilly since 2020
1550+ opinions with 4.81 rating (one of the best performing expert)

Latest Top Picks

Stock Opinions by The Panic-Proof Portfolio (Stockchase Research)

Most recent Opinions go here

Be up to date, don’t miss your chance.

TOP PICK
Stockchase Research Editor: Michael O'Reilly

The salon operator of the SuperCuts brand recently reported an operating income increase of 15% along with a 22% growth in revenues.  Cash reserves are growing, albeit along with rising debt.  It trades at 11x earnings and trades under book value.  We recommend maintaining a stop at $19, looking to achieve $36 -- upside potential of 28%.  Yield 0% 

(Analysts’ price target is $40.00)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

The diversified holder of financial equity assets uses leverage to further enhance market returns of its portfolio.  Currently the company holds about 12% debt, which is trending lower.  Its yield is backed by a payout ratio under 15% of cash flow.  It presently trades at 5x earnings, under book value and supports a 13% ROE.  We recommend trailing up the stop (from $35.50) to $40.50, looking to achieve $58.00 -- upside potential of 28%.  Yield 2.3%

(Analysts’ price target is $169.00)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Stockchase Research Editor: Michael O'Reilly

RPRX is the largest buyer of biopharma royalties in the world.  They draw their value from providing innovative financing to pharma partners, while sharing in the top line revenue of the new products developed.  Deloitte just released a study highlighting the importance of royalties in new pharma development -- and RPRX leads the way.  It trades at 8x earnings, 2.2x book and supports a 25% ROE.  Quarterly cashflow is cautiously being used to aggressively buy back shares.  We recommend maintaining a stop at $34.50, looking to achieve $45 -- upside potential of 25%.  Yield 2.4%

(Analysts’ price target is $44.67)
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick May 01/25, Up 182.6%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with HUT is progressing well.  To remain disciplined, we recommend trailing up the stop (from $28.50) to $33.00 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jul 08/25, Up 82.9%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with AEM is progressing well.  To remain disciplined, we recommend trailing up the stop (from $161) to $177 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick May 08/25, Up 73.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with NCSM is progressing well.  To remain disciplined, we recommend trailing up the stop (from $27.50) to $30.50 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Apr 29/25, Up 48.1%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with TA is progressing well.  To remain disciplined, we recommend trailing up the stop (from $14.50) to $16.00 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jun 12/25, Up 45.6%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with DLO is progressing well.  To remain disciplined, we recommend trailing up the stop (from $11) to $12 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Apr 24/25, Up 43.5%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with VIPS is progressing well.  To remain disciplined, we recommend trailing up the stop (from $13.50) to $15.00 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Jul 01/25, Up 35.1%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with UAL is progressing well.  To remain disciplined, we recommend trailing up the stop (from $86) to $95 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Aug 07/25, Up 34.7%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with MCY is progressing well.  To remain disciplined, we recommend trailing up the stop (from $65.50) to $74.00 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Aug 07/25, Up 31.9%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with APA is progressing well.  To remain disciplined, we recommend trailing up the stop (from $15) to $19 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick May 27/25, Up 31.7%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with DFH is progressing well.  To remain disciplined, we recommend trailing up the stop (from $23) to $26 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Aug 05/25, Up 22.1%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with ENVA is progressing well.  To remain disciplined, we recommend trailing up the stop (from $77) to $107 at this time.  

premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
(A Top Pick Apr 22/25, Up 23%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with GRBK is progressing well.  To remain disciplined, we recommend trailing up the stop (from $60) to $67 at this time.  

Showing 1 to 15 of 3,338 entries